Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort

NCT04580381 ·Status: COMPLETED

A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)

NCT00424788 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)

NCT00559702 ·Status: COMPLETED ·Phase: PHASE1

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00097760 ·Status: COMPLETED ·Phase: PHASE2

Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis

NCT01071512 ·Status: COMPLETED ·Phase: NA

Natalizumab Subcutaneous Immunogenicity and Safety Study

NCT02142192 ·Status: TERMINATED ·Phase: PHASE2

Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab

NCT01250678 ·Status: UNKNOWN

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study

NCT00937677 ·Status: COMPLETED

Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT01440101 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

NCT01541618 ·Status: COMPLETED

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

NCT01591551 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®

NCT04115488 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT02142205 ·Status: COMPLETED ·Phase: PHASE4

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

NCT02342704 ·Status: TERMINATED ·Phase: PHASE4

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

NCT05418010 ·Status: RECRUITING ·Phase: PHASE2

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

NCT00030966 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

NCT03689972 ·Status: COMPLETED ·Phase: PHASE3

Clinical Disease Activity With Long Term Natalizumab Treatment

NCT02677077 ·Status: COMPLETED

Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design

NCT01945359 ·Status: COMPLETED

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

NCT01485003 ·Status: COMPLETED

Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis

NCT04777539 ·Status: COMPLETED

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

NCT02241785 ·Status: TERMINATED ·Phase: PHASE4

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05925049 ·Status: ACTIVE_NOT_RECRUITING

Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

NCT03046251 ·Status: COMPLETED ·Phase: PHASE4

Natalizumab (Tysabri) Re-Initiation of Dosing

NCT00297232 ·Status: TERMINATED ·Phase: PHASE3